Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Queensland Health

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,977,257

« Back to Dashboard

Which drugs does patent 6,977,257 protect, and when does it expire?

Patent 6,977,257 protects ABILIFY and is included in one NDA. There have been three Paragraph IV challenges on Abilify.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in thirty-seven countries.

Summary for Patent: 6,977,257

Title: Aripiprazole oral solution
Abstract:The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
Inventor(s): Parab; Prakash V. (Monroe Township, NJ), Chou; Joyc Tianw i (Fremont, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/131,304
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
SOLUTION;ORAL021713-001Dec 10, 2004DISCNYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,977,257

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic20032821► Subscribe
Czech Republic306181► Subscribe
Argentina033168► Subscribe
Austria537831► Subscribe
Australia2002254722► Subscribe
Denmark1381367► Subscribe
Estonia200300523► Subscribe
Estonia05581► Subscribe
European Patent Office1381367► Subscribe
European Patent Office2436384► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Boehringer Ingelheim
Queensland Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus